Biogen is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. The company focuses on addressing serious conditions such as multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, among others. Through advanced research and development, Biogen aims to create breakthrough treatments that improve the lives of patients and their families, and it leverages its expertise in biologics and immunology to bring novel solutions to market. Additionally, Biogen is committed to advancing science and fostering collaboration within the medical and scientific communities to further enhance patient care. Read More
As of April 3, 2026, the American equity market is witnessing a historic "Great Rotation" that many analysts believe could define the latter half of the decade. For the first time in over a quarter-century, the valuation gap between the S&P 500 (INDEXSP:INX) and the Russell 2000 (INDEXRUSSELL:
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive technical breakout followed the announcement that Biogen (Nasdaq: BIIB) has entered into a definitive agreement to acquire the leader
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion in cash. The deal, valued at $41 per
A new wave of market-moving developments across biotech, defense technology, and emerging growth companies is putting Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), Virtuix Holdings, Inc. (NASDAQ: VTIX) , PMGC Holdings Inc. (NASDAQ: ELAB) , and Artelo Biosciences, Inc. (NASDAQ: ARTL) firmly on investor watchlists. Biotech M&A activity, defense-driven VR adoption, strategic capital deployment, and fresh funding catalysts are all contributing to rising investor interest across multiple high-growth sectors.
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY). Once a steady mid-tier giant known for insulin and antidepressants, Lilly has transformed into the world’s first trillion-dollar healthcare titan. Today’s announcement—a definitive $6.3 [...]
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®.
CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the High Dose Regimen of SPINRAZA® (nusinersen), which is comprised of 50 mg/5 mL and 28 mg/5 mL doses, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA). Backed by more than 10 years of clinical data supporting the Low Dose Regimen of SPINRAZA (12 mg), High Dose SPINRAZA was designed to deliver a higher concentration of drug through both the loading and maintenance dosing phases, to provide a new option in response to the ongoing needs of the community.
CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). Litifilimab is the first humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2), which has the potential to become the first innovative therapy approved for CLE in 70 years. Part A of AMETHYST evaluated the efficacy and safety of litifilimab through week 24, with reductions in skin disease activity reported across several measures. Results are consistent with the earlier positive Phase 2 LILAC study reported in The New England Journal of Medicine. Phase 2 results from LILAC and AMETHYST supported litifilimab’s recently granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation. Results are being presented today at the American Academy of Dermatology (AAD) Annual Meeting.
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI) for its lead asset, AVLAYAH™ (tividenofusp alfa-eknm). This represents more than just a new treatment for Hunter Syndrome; it marks the first time in medical history that [...]
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaking data from Part A (Phase 2) of the AMETHYST Phase 2/3 study will be presented that highlight litifilimab’s effect on cutaneous lupus erythematosus (CLE) disease activity. Litifilimab is a potential first in-class, monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and was the first investigational therapy to show positive results in CLE, as shown in the Phase 2 LILAC study. Additional presentations at AAD will provide new insights into measures used to assess the severity of CLE disease activity in both clinical trials and clinical practice.
CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) presented additional results from the Phase 1b study of salanersen, an investigational novel antisense oligonucleotide (ASO) given once a year for spinal muscular atrophy (SMA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. The study evaluated salanersen in children who had suboptimal clinical status despite prior administration of gene therapy (onasemnogene abeparvovec-xioi). Salanersen was generally well-tolerated. Participants experienced a slowing of neurodegeneration and functional improvement, including achievement of new World Health Organization (WHO) motor milestones, following initiation of salanersen. These new results include a minimum of one year of follow-up for all participants, building on the interim study data presented at Cure SMA 2025. The company also presented the study designs of the Phase 3 salanersen clinical trials.
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq: XENE). Long a favorite of biotech specialists for its deep expertise in ion-channel biology, Xenon has officially transitioned from a "high-potential" R&D firm to a "pre-commercial" titan following [...]
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...
CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, including high dose nusinersen and salanersen, at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (March 8-11, 2026) and 5th International Scientific Congress on SMA (SMA Europe 2026; March 11-14, 2026).
